PHOENIX — A Banner Health doctor in Phoenix is using an investigational treatment for coronavirus patients focused on inhaled nitric oxide.
The treatment is called INOpulse and is said to be the only treatment designed to deliver a targeted dose of nitric oxide.
“In previous clinical studies, nitric oxide was found to inhibit the replication of severe acute respiratory syndrome-related coronaviruses (SARS-COV)—similar to the novel COVID-19—while increasing oxygen saturation and blood flow,” a press release says.
The FDA approved the Bellerophon Therapeutics request to begin Phase 3 of the INOpulse study in up to 500 patients earlier in May.
So far, doctors have already treated more than 50 COVID-19 patients with the INOpulse system, and the “therapy appeared to improve oxygenation.”
The treatments are being led by Thomas Ardiles, M.D., Clinical Assistant Professor at University of Arizona College of Medicine Phoenix & Pulmonary and Critical Care Physician at Banner – University Medical Center Phoenix.
